Navigation Links
CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
Date:2/3/2010

VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE  CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2010 BIO CEO & Investor Conference.  Hosted by the Biotechnology Industry Organization (BIO), the conference will take place February 8-9 at the Waldorf=Astoria in New York.

Mr. Kersten's presentation will be on Tuesday, February 9th, at 1:30 p.m. EST.  The presentation will be webcast live with slides and archived until May 11, 2010.  The webcast can be accessed at http://www.veracast.com/webcasts/bio/ceoinvestor2010/05209268.cfm.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine® is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to treat H1N1 hospitalized patients using its L.E.A.P.S.™ technology platform.  This investigational treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu.  This investigational treatment is currently being tested in a clinical study at Johns Hopkins University.  The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

About The BIO CEO & Investor Conference

Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry.  The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry.  This years' conference will feature corporate presentations from more than 120 companies, workshops featuring leading experts on specific therapeutic and technology topics, plenary and panel sessions on timely business issues and industry trends, many opportunities to schedule one-on-one meetings, as well as numerous networking opportunities.  For more information, visit www.ceo.bio.org.

SOURCE CEL-SCI Corporation

RELATED LINKS
http://www.cel-sci.com

'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
2. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
3. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
6. CEL-SCI Expands H1N1 Flu Virus Work
7. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
8. CEL-SCI Posts New Corporate Presentation to Website
9. CEL-SCI Corporation Releases Letter to Shareholders
10. CEL-SCI Corporation Releases Letter to Shareholders
11. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Alberta , January 23, 2017 ... del riñón (r enal) y ... sola dosis de a pabetalone    ... hoy los resultados preliminares de un ensayo en fase ... con discapacidad de riñón (renal) severa. Los datos demostraron ...
(Date:1/23/2017)... , January 23, 2017 Stock-Callers.com today ... Inc. (NASDAQ: CPRX ), Sophiris Bio Inc. (NASDAQ: ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: AGRX ... turned somewhat lower in late trade on Friday, January 20 ... about 0.3%, while shares of health care companies in the ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are factors ... BCC Research reveals in its new report that markets in developing ... strong growth due to rising government healthcare spending, increased levels of healthcare ... Reading ... BCC ...
Breaking Medicine Technology:
(Date:1/23/2017)... Dc (PRWEB) , ... January 23, 2017 , ... ... American University is taught by healthcare management and evaluation leaders with decades of ... fee-for-service to pay-for-value in the United States healthcare system, there is a renewed ...
(Date:1/23/2017)... ... 23, 2017 , ... Moisture measurement is a necessary process ... paramount to success. Selecting an inappropriate measurement method can cause costly errors, and ... same equipment. Rare or expensive substances are wasted and production may even be ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... gynecological care and gynecological services for women of all ages. The ... a wide variety of reproductive services from routine health screenings to diagnosing and ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating ... of Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the ... years, a preacher for over nineteen, a pastor for over fifteen years. He is ...
(Date:1/22/2017)... ... 2017 , ... Medical lab testing through hospitals and other traditional ... test will take days to arrive to the end customer, having to travel through ... their lab tests, bypassing the cost and delay of traditional means. Now all employees ...
Breaking Medicine News(10 mins):